About Evolus
Evolus is a company based in Irvine (United States) founded in 2012.. Evolus has raised $500 thousand across 3 funding rounds from investors including Daewoong Pharmaceutical. The company has 332 employees as of December 31, 2024. Evolus offers products and services including Jeuveau and Evolysse. Evolus operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Irvine, United States
- Employees 332 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Evolus, Inc. Common Stock
-
Annual Revenue
$266.27 M31.76as on Dec 31, 2024
-
Net Profit
$-50.42 M18.26as on Dec 31, 2024
-
EBITDA
$-21.21 M29.84as on Dec 31, 2024
-
Total Equity Funding
$500 K (USD)
in 3 rounds
-
Latest Funding Round
$20.01 M (USD), Post-IPO
Apr 25, 2022
- Investors
-
Employee Count
332
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evolus
Evolus is a publicly listed company on the NASDAQ with ticker symbol EOLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evolus
Evolus offers a comprehensive portfolio of products and services, including Jeuveau and Evolysse. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Improves appearance of moderate to severe frown lines temporarily.
Softens dynamic facial wrinkles and folds via injection.
Unlock access to complete
Unlock access to complete
Funding Insights of Evolus
Evolus has successfully raised a total of $500K across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20.01 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $20.0M
-
First Round
First Round
(22 Mar 2013)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2022 | Amount | Post-IPO - Evolus | Valuation |
investors |
|
| Jul, 2020 | Amount | Post-IPO - Evolus | Valuation |
investors |
|
| Mar, 2013 | Amount | Seed - Evolus | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Evolus
Evolus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for gastrointestinal disorders and related diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Evolus
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Evolus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Evolus Comparisons
Competitors of Evolus
Evolus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Evolus
Frequently Asked Questions about Evolus
When was Evolus founded?
Evolus was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Evolus located?
Evolus is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Who is the current CEO of Evolus?
Murthy Simhambhatla is the current CEO of Evolus.
Is Evolus a funded company?
Evolus is a funded company, having raised a total of $500K across 3 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Mar 22, 2013.
How many employees does Evolus have?
As of Dec 31, 2024, the latest employee count at Evolus is 332.
What is the annual revenue of Evolus?
Annual revenue of Evolus is $266.27M as on Dec 31, 2024.
What does Evolus do?
Evolus was founded in 2012 and is headquartered in Irvine, United States. Operations center on the development of self-pay aesthetic products within the biotechnology sector. The lead product candidate, DWP-450, an injectable 900 kDa purified botulinum toxin type A complex, is currently in Phase II clinical trials for moderate-to-severe glabellar lines. Focus remains on advancing injectable aesthetic solutions.
Who are the top competitors of Evolus?
Evolus's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
What products or services does Evolus offer?
Evolus offers Jeuveau and Evolysse.
Is Evolus publicly traded?
Yes, Evolus is publicly traded on NASDAQ under the ticker symbol EOLS.
Who are Evolus's investors?
Evolus has 1 investor. Key investors include Daewoong Pharmaceutical.
What is Evolus's ticker symbol?
The ticker symbol of Evolus is EOLS on NASDAQ.